Alnylam Pharma (ALNY) Misses Q4 EPS by 11c
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $298.76 -4.49%
Revenue Growth %: +70.6%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
CCEL, FEIM, PLG, More
Revenue Growth %: +70.6%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.07), $0.11 worse than the analyst estimate of ($0.96). Revenue for the quarter came in at $7.6 million versus the consensus estimate of $9.1 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
- Stifel: 'We expect IONS shares to trade lower today and ALNY shares to be volatile'
- Alnylam Pharmaceuticals (ALNY) PT Raised to $400 at Morgan Stanley
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
